2017
DOI: 10.14789/jmj.63.17
|View full text |Cite
|
Sign up to set email alerts
|

Heat Shock Protein 27 (HSP27) As a Therapeutic Target in Ischemic Stroke and Neurodegenerative Disorders

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 33 publications
0
3
0
Order By: Relevance
“…Overexpressing HSP27 in HSP27 transgenic mice prevented cells from suffering further neuronal damage by preventing ASK1-dependent MKK4/JNK activation (23). Intravenous injection of HSP27 in the MCAO mouse model also showed inhibition of apoptosis and inflammatory responses (7). However, the antioxidant benefits that HSP27 has to exist during its large oligomeric conditions (24).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Overexpressing HSP27 in HSP27 transgenic mice prevented cells from suffering further neuronal damage by preventing ASK1-dependent MKK4/JNK activation (23). Intravenous injection of HSP27 in the MCAO mouse model also showed inhibition of apoptosis and inflammatory responses (7). However, the antioxidant benefits that HSP27 has to exist during its large oligomeric conditions (24).…”
Section: Discussionmentioning
confidence: 99%
“…Heat shock protein 27 (HSP27) can function as an antioxidant by increasing intracellular glutathione levels to reduce ROS (7). HSP27, under stress conditions, will interact with phosphatidylinositol 3-kinase (PI3-K), which can increase the expression of protein kinase B (Akt).…”
mentioning
confidence: 99%
“…Based on the result that has been reported intravenously administration of HSP27 showed protection of the brain in different stroke rat models. 98 The authors claim that they did not observe any significant adverse effect of HSP27. Further studies are needed in order to develop HSP27 intravenous therapy for the treatment of stroke.…”
Section: Therapeutical Targeting/inhibitionmentioning
confidence: 98%